Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
Globe Newswire•27/10/2026•07:30 ET
0
Key Highlights
- ➤Cerenome will present interim data from the first 10 patients in ReSPECT-LMM.
- ➤ReSPECT-LMM evaluates repeated REYOBIQ doses for leptomeningeal metastases under an FDA-approved IND.
- ➤Company targets an FDA-aligned Phase 2 dose-randomization study in 2027.
- ➤Poster will report interim safety, dosimetry, biomarker, and individual treatment-course data.
- ➤REYOBIQ remains investigational and has no FDA or other regulatory approval.
Expert Statements
Eric J. Daniels, Chief Development Officer of Cerenome
“Improving outcomes for patients with leptomeningeal metastases requires progress in how we diagnose, treat, and monitor the disease.”
Eric J. Daniels, Chief Development Officer of Cerenome
“Our participation at SNO will bring these priorities together through discussions of our CNSide and REYOBIQ platforms, real-world patient management, and the research needed to advance personalized CNS cancer care.”
Eric J. Daniels, Chief Development Officer of Cerenome
“The ReSPECT-LMM data is an interim look at an ongoing study, and we look forward to sharing additional data.”
Company to provide latest clinical trial data and highlight evolving approaches to leptomeningeal metastases diagnosis and treatment in a company sponsored symposium
2026 SNO Annual Meeting to be held on November 12-15 in Philadelphia
Get started
Create a free account to read the full story.